On 9-12 June 2022, this year’s congress was held in Denver, Colorado, as both an in-person and as a virtual experience.
More than a third of migraine patients not adequately responding to anti-CGRP mAbs at week 12 of treatment may respond later, according to latest data from a multicentre, longitudinal, cohort, real life study carried out at 16 Italian headache centres. Response rates of >50% response were evaluated in all consecutive patients with high frequency episodic …
Read more »Migraine symptoms related to peripheral trigeminal sensitisation may predict response (>50%) and super-response (>75%) to anti-CGRP monoclonal antibodies (mAbs). In an analysis of 864 patients with high frequency episodic migraine (HFEM) or chronic migraine (CM), treated with erenumab, galcanezumab or fremanezumab for more than 24 weeks, unilateral pain (UP) + unilateral cranial autonomic symptoms (UAs) …
Read more »Nearly two thirds (63%) of patients with migraine who report at least four monthly headache days (MHDs) have never used preventive medication, according to data from the US cohort in the 2021 Chronic Migraine Epidemiology and Outcomes-International (CaMEO-I) study. A further 14.5% had discontinued preventive medication, and only 22.5% said they were currently on preventive …
Read more »More than 80% of patients with migraine who took rimegepant as both preventive and acute treatment achieved ≥50% reduction in moderate or severe monthly migraine days (MMDs) in weeks 49-52 of an open label extension (OLE) study reported at the congress.1 Through the 52 week OLE phase, MMD frequency consistently declined – by a mean …
Read more »Patients with episodic migraine who achieve an initial ≥50% reduction in monthly migraine days (MMDs) with atogepant generally sustain this response over 12 and 52 weeks of continued treatment, according to post hoc analyses of two Phase 3 trials of efficacy and safety (NCT03777059 and NCT03700320). In the 12-week, ADVANCE study, 70.8-81.1% of participants who …
Read more »Latest analysis of data from the COURAGE study of ubrogepant in combination with onabotulinumtoxinA has shown that seven out of 10 patients with high levels of migraine disability were satisfied with treatment. Of 116 patients, 81 (69.8%) were satisfied (16.7% extremely satisfied, 24.1% very satisfied, 19% satisfied). Of respondents, 86.9% had severe or very severe …
Read more »Growing evidence of the efficacy and tolerability of combined CGRP mAb and gepant treatment is emerging from clinical practice. Results of a retrospective chart review of 55 adult patients carried out at a New York practice showed that adding fremanezumab to gepant therapy reduced average monthly migraine days (MMDs) by -6.5 days (standard deviation [SD] …
Read more »A higher resilience score is inversely correlated with Migraine Disability Assessment (MIDAS) score, and greater levels of anxiety and depression are associated with increased levels of headache-related disability. In a study carried out to explore discordance between MIDAS scores and functional ability in practice, 160 patients with primary headache disorders completed five validated measures in …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
